MedTrace Logo

Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients

NCT00673582 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2009-08-25

No results posted yet for this study

Summary

Rosuvastatin is a drug used to lower cholesterol, which also has other cardiovascular benefits. The goal of this project is to determine if rosuvastatin is effective at slowing the development of heart disease in people with HIV. We expect that after 2 years of treatment people treated with rosuvastatin will show significantly better results than people treated with a placebo.

Conditions

Interventions

DRUG

Rosuvastatin

10 mg/day rosuvastatin

DRUG

Placebo

Placebo, 10 mg a day for 96 weeks

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • CIHR Canadian HIV Trials Network

    collaborator NETWORK

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Greg Bondy, MD · University of British Columbia

  • Marianne Harris, MD · University of British Columbia

  • Marek Smeija, MD · University of British Columbia

  • Joel Singer, MD · University of British Columbia

  • G.B. John Mancini, MD · University of British Columbia

  • Sammy Chan, MD · University of British Columbia

  • Julio Montaner, MD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-12-31
Completion
2013-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00673582 on ClinicalTrials.gov